Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

By Marcus Bantscheff, C. Hopf, Mikhail M. Savitski, A. Dittmann, P. Grandi, A. Michon, J. Schlegl, Yann Abraham, Isabelle Becher, G. Bergamini and 14 more. Nature Biotechnology, 2011

654 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0b28510163629d48d54138adc018ae1418844ebe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ricky W. Johnstone
2. M. Dawson
3. Tony Kouzarides
4. Stefan Schreiber
5. Todd R. Golub
6. David Wadden
7. Peyton Greenside
8. Nathanael S. Gray

In Oncology

1. M. Dawson
2. Tony Kouzarides
3. Ricky W. Johnstone
4. Nathanael S. Gray
5. J. Lamb

Citations in the corpus

• Cancer epigenetics: from mechanism to therapy. (2012, background): “Substrate specificity for these enzymes is largely mediated by components of multisubunit complexes in which HDACs are found, such as Mi2/NuRD, Sin3A, and Co-REST (Bantscheff et al., 2011; Xhemalce et al., 2011).”
• New and emerging HDAC inhibitors for cancer treatment. (2014, positive): “HDACis can be used as “bait” to explicitly discriminate between multiprotein complexes containing the same HDAC target (34).”
• A Next Generation Connectivity Map: L1000 platform and the first 1,000,000 profiles (2017, background): “The pan-HDAC inhibitors generally cluster together, distinct from the more isoform-selective compounds, suggesting that gene expression can be used to further stratify compounds within the same class (Fass et al. 2010; Bradner et al. 2010; Butler et al. 2010; Kwon et al. 1998; Arts et al. 2009; Hagg”